Osaka, Japan

Atsushi Hiramatsu

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 6.2

ph-index = 1


Company Filing History:


Years Active: 2018-2023

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Atsushi Hiramatsu: Innovator in Vascular Therapeutics

Introduction

Atsushi Hiramatsu is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target vascular occlusive diseases. With a total of 6 patents to his name, Hiramatsu's work is recognized for its potential impact on medical treatments.

Latest Patents

One of Hiramatsu's latest patents involves a Dihydroindolizinone derivative, which is a compound represented by a specific general formula. This compound acts as a potent FXIa inhibitor and exhibits excellent oral absorption properties and kinetics in blood. It is capable of exerting a strong anti-coagulation activity over an extended period after oral administration. Notably, there is a discrepancy between its anti-coagulation activity and its CYP-inhibiting activity. This makes the compound or its derivatives suitable for use as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

Career Highlights

Hiramatsu is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate and develop new therapeutic agents. His work has been instrumental in advancing the understanding and treatment of vascular conditions.

Collaborations

Hiramatsu collaborates with notable colleagues, including Motoyuki Tanaka and Takashi Kondo. Their combined expertise contributes to the success of their projects and the advancement of pharmaceutical research.

Conclusion

Atsushi Hiramatsu is a key figure in the field of vascular therapeutics, with a focus on innovative compounds that can significantly improve patient outcomes. His contributions through patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…